Home Cart Sign in  
Chemical Structure| 496775-61-2 Chemical Structure| 496775-61-2

Structure of Eltrombopag
CAS No.: 496775-61-2

Chemical Structure| 496775-61-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Eltrombopag is an agonist of thrombopoietin-receptor (TpoR) and can stimulate thrombopoiesis.

Synonyms: SB-497115

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Eltrombopag

CAS No. :496775-61-2
Formula : C25H22N4O4
M.W : 442.47
SMILES Code : O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O
Synonyms :
SB-497115
MDL No. :MFCD20926253
InChI Key :SVOQIEJWJCQGDQ-UHFFFAOYSA-N
Pubchem ID :135449332

Safety of Eltrombopag

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia and the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Otherwise, Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1].[2].[3].[4].[5].

In Vitro:

Cell Line
Concentration Treated Time Description References
4T1 cells 5 μM 12 hours Inhibited the migration and invasion of 4T1 cells PMC9963984
RAW264.7 cells 10 μM 12 hours Inhibited the expression of Vegf-c in RAW264.7 cells PMC9963984
human primary cells from cord blood 500-2000 ng/mL 13 days Eltrombopag stimulates the MK output and proplatelet formation by 4-fold at day 13 of culture compared to 10 ng/mL TPO PMC5479610
BaF3 cells 1 μM 30 minutes To test the inhibitory effect of Eltrombopag on TET activity, results showed that Eltrombopag inhibited TET activity, independent of TPOR signaling PMC8843742
32D cells 1 μM 30 minutes To test the inhibitory effect of Eltrombopag on TET activity, results showed that Eltrombopag inhibited TET activity, independent of TPOR signaling PMC8843742
Mouse bone marrow mononuclear cells 1 μM 30 minutes To test the inhibitory effect of Eltrombopag on TET activity, results showed that Eltrombopag inhibited TET activity PMC8843742
Mesenchymal stromal cells from immune thrombocytopenia patients (ITP-MSCs) 6 µM 48 hours To evaluate the effect of Eltrombopag on the survival and activity of ITP-MSCs, results showed that Eltrombopag restored the survival and activity of ITP-MSCs and indirectly promoted their survival and proliferation by modulating iron metabolism. PMC9303225

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice C57BL/6J mice Oral 50 mg/kg Once daily for 3 months To test the inhibitory effect of Eltrombopag on TET2, results showed that Eltrombopag significantly increased bone marrow cell counts in Tet2+/+ mice but had no significant effect in Tet2-/- mice PMC8843742
BALB/c mice Breast cancer lung metastasis model Intraperitoneal injection 75 mg/kg Every three days for 9 days Inhibited breast cancer lung metastasis PMC9963984

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00529568 Hepatitis C, Chronic Phase 3 Completed - -
NCT00370331 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << Phase 3 Completed - -
NCT01864512 - Withdrawn(No eligible patient ... More >>was enrolled.) Less << April 2014 China, Shandong ... More >> Qilu Hospital, Shandong University Jinan, Shandong, China, 250012 Less <<
NCT00370331 - Completed - -
NCT00833378 Hepatitis C Phase 1 Completed - United States, New York ... More >> GSK Investigational Site Buffalo, New York, United States, 14202 Less <<
NCT03025698 Aplastic Anemia Phase 2 Recruiting April 1, 2024 -
NCT00688272 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << Phase 1 Completed - United Kingdom ... More >> GSK Investigational Site Dundee, United Kingdom, DD1 9SY Less <<
NCT00529568 - Completed - -
NCT01623167 Severe Aplastic Anemia Phase 1 Phase 2 Recruiting January 30, 2024 United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov Less <<
NCT01433978 Idiopathic Thrombocytopenic Pu... More >>rpura Less << Phase 3 Terminated(Study was terminate... More >>d early due to significant enrollment challenges.) Less << - United States, South Dakota ... More >> Prairie Lakes Health Care System Watertown, South Dakota, United States Less <<
NCT01890746 Leukaemia, Acute Phase 2 Completed - -
NCT01433978 - Terminated(Study was terminate... More >>d early due to significant enrollment challenges.) Less << - -
NCT01113502 Acute Myelogenous Leukemia (AM... More >>L) Less << PHASE1|PHASE2 TERMINATED 2015-11-10 Abramson Cancer Center of the ... More >>University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT00909363 Wiskott-Aldrich Syndrome ... More >> Thrombocytopenia Bleeding Less << Phase 2 Active, not recruiting June 2020 United States, New York ... More >> Weill Cornell Medical College New York, New York, United States, 10065 Less <<
NCT00359463 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << Phase 1 Completed - United States, Florida ... More >> GSK Investigational Site Gainesville, Florida, United States, 32608 GSK Investigational Site Orlando, Florida, United States, 32809 Australia, New South Wales GSK Investigational Site Randwick, Sydney, New South Wales, Australia, 2031 Australia, South Australia GSK Investigational Site Adelaide, South Australia, Australia, 5000 New Zealand GSK Investigational Site Christchurch, New Zealand, 8011 Less <<
NCT01440374 Thrombocytopaenia Phase 2 Completed - -
NCT01890746 - Completed - -
NCT00861601 - Completed - -
NCT01416311 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << COMPLETED 2020-10-16 -
NCT01440374 - Completed - -
NCT00903422 Myelodysplastic Syndrome Phase 1 Completed - -
NCT00861601 Liver Diseases Phase 2 Completed - Japan ... More >> GSK Investigational Site Fukuoka, Japan, 810-8563 GSK Investigational Site Fukuoka, Japan, 814-0180 GSK Investigational Site Fukuoka, Japan, 815-8555 GSK Investigational Site Fukuoka, Japan, 830-0011 GSK Investigational Site Fukuoka, Japan, 839-0863 GSK Investigational Site Kagoshima, Japan, 890-8520 GSK Investigational Site Kumamoto, Japan, 860-8556 GSK Investigational Site Kumamoto, Japan, 862-8655 GSK Investigational Site Nagasaki, Japan, 856-8562 GSK Investigational Site Oita, Japan, 879-5593 Less <<
NCT00442871 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << Phase 1 Completed - United States, Florida ... More >> GSK Investigational Site Gainesville, Florida, United States, 32608 United States, Minnesota GSK Investigational Site Saint Paul, Minnesota, United States, 55114-1067 Less <<
NCT02928419 Myelodysplastic Syndromes Phase 2 Terminated("the study has been... More >> closed due to a low rate of patient enrollment (2 patients since the start of the trial)") Less << - -
NCT01064336 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << COMPLETED 2025-07-14 -
NCT00908037 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << Phase 2 Completed - -
NCT01098487 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << Phase 4 Completed - -
NCT00908037 - Completed - -
NCT01098487 - Completed - -
NCT01147809 - Completed - -
NCT00540423 - Completed - -
NCT02877212 Immune Thrombocytopenic Purpur... More >>a (ITP) Less << PHASE3 UNKNOWN 2025-09-17 Armed Forces Bone Marrow Trans... More >>plant Centre, Rawalpindi, Punjab, 46000, Pakistan Less <<
NCT02446145 Acute Myeloid Leukemia Phase 2 Recruiting May 2019 Germany ... More >> Uniklinik RWTH Aachen Recruiting Aachen, Germany Contact: Martina Crysandt, MD          Charite Campus Benjamin Franklin Not yet recruiting Berlin, Germany Contact: Claudia Baldus, Prof.          Klinikum Chemnitz GmbH Recruiting Chemnitz, Germany Contact: Mathias Hänel, MD          Universitätsklinikum Dresden Recruiting Dresden, Germany Contact: Uwe Platzbecker, Prof.          Marienhospital Düsseldorf GmbH Not yet recruiting Düsseldorf, Germany Contact: Aristoteles Giagounidis, MD          Universitätsklinikum Essen Recruiting Essen, Germany Contact: Richard Noppeney, MD          Universitätsklinikum Halle (Saale) Recruiting Halle, Germany Contact: Petra Tschanter, MD          St. Marien-Hospital Hamm Not yet recruiting Hamm, Germany Contact: Heinz A Dürk, MD          Klinikum rechts der Isar der TU München Not yet recruiting München, Germany Contact: Katharina Götze, MD          Klinikum Nürnberg-Nord Recruiting Nürnberg, Germany Contact: Kerstin Schäfer-Eckart, MD          Medizinisches Versorgungszentrum für Blut- und Krebserkrankungen Recruiting Potsdam, Germany Contact: Hartmut Linde, MD          Wissenschaftskontor Nord GmbH & Co KG Not yet recruiting Rostock, Germany Contact: Andreas Lück, MD          Diakonie-Klinikum Schwäbisch Hall gGmbH Recruiting Schwäbisch Hall, Germany Contact: Thomas Geer, MD          Rems-Murr-Klinikum Winnenden Recruiting Winnenden, Germany Contact: Stefani Parmentier, MD          Universitätsklinikum Würzburg Not yet recruiting Würzburg, Germany Contact: Volker Kunzmann, Prof. Less <<
NCT00358540 Thrombocytopaenia Phase 1 Completed - United States, California ... More >> GSK Investigational Site Santa Monica, California, United States, 90403 United States, Florida GSK Investigational Site Miami, Florida, United States, 33136 GSK Investigational Site Tampa, Florida, United States, 33612 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19106 United States, South Carolina GSK Investigational Site Greenville, South Carolina, United States, 29605 United States, Texas GSK Investigational Site Dallas, Texas, United States, 75246 GSK Investigational Site Houston, Texas, United States, 77030-4009 Less <<
NCT01328587 Moderate Aplastic Anemia|Unili... More >>neage Bone Marrow Failure Disorders Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-06-30 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT01147809 Thrombocytopaenia Phase 2 Completed - -
NCT00424177 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << Phase 2 Completed - Germany ... More >> GSK Investigational Site Hannover, Niedersachsen, Germany, 30625 GSK Investigational Site Berlin, Germany, 13353 Russian Federation GSK Investigational Site Moscow, Russian Federation, 125167 Less <<
NCT00487968 Healthy Subjects ... More >> Purpura, Thrombocytopenic, Idiopathic Less << Phase 1 Completed - United States, Kansas ... More >> GSK Investigational Site Overland Park, Kansas, United States, 66211 Less <<
NCT00540423 Chronic Idiopathic Thrombocyto... More >>penic Purpura Purpura, Thrombocytopenic, Idiopathic Less << Phase 3 Completed - Japan ... More >> GSK Investigational Site Gifu, Japan, 503-8502 GSK Investigational Site Hiroshima, Japan, 734-8551 GSK Investigational Site Ibaraki, Japan, 305-8576 GSK Investigational Site Osaka, Japan, 565-0871 GSK Investigational Site Osaka, Japan, 596-8501 GSK Investigational Site Tochigi, Japan, 329-0498 GSK Investigational Site Tokyo, Japan, 160-8582 Less <<
NCT02158936 Thrombocytopaenia Phase 3 Terminated - -
NCT02912208 Myelodysplastic Syndromes ... More >> Thrombocytopenia Less << Phase 2 Recruiting June 2019 -
NCT02834286 Immune Thrombocytopenia Phase 2 Unknown September 2017 Mexico ... More >> Servicio de Hematología, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León Recruiting Monterrey, Nuevo León, Mexico, 64460 Contact: Perla R Colunga, MD    +558110761973    colunga.perla@gmail.com    Principal Investigator: David Gómez-Almaguer, MD          Sub-Investigator: Perla R. Colunga-Pedraza, MD          Sub-Investigator: Olga Cantú-Rodríguez, MD          Sub-Investigator: César H. Gutiérrez-Aguirre, MD          Sub-Investigator: Mónica Sánchez-Cárdenas, MD          Sub-Investigator: José C Jaime-Pérez, MD          Sub-Investigator: Luz Tarín-Arzaga Less <<
NCT02158936 - Terminated - -
NCT01772420 Adult Myelodysplastic Syndrome... More >> Anemia Chronic Myelomonocytic Leukemia Less << Phase 2 Unknown - United States, Kansas ... More >> University of Kansas Cancer Center Recruiting Kansas City, Kansas, United States, 66160 Contact: Suman Kambhampati    913-588-6029    skambhampati@kumc.edu    Principal Investigator: Suman Kambhampati          United States, New York Albert Einstein College of Medicine Recruiting Bronx, New York, United States, 10461 Contact: Amit K. Verma    718-430-8761    amit.verma@einstein.yu.edu    Principal Investigator: Amit K. Verma Less <<
NCT01657552 Thrombocytopaenia Phase 1 Completed - United States, Maryland ... More >> GSK Investigational Site Baltimore, Maryland, United States, 21225 Less <<
NCT01927731 Bone Marrow Transplantation Re... More >>cipient Cord Blood Transplant Recipient Hematopoietic Cell Transplantation Recipient Less << Phase 2 Active, not recruiting October 31, 2019 United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00903929 Thrombocytopenia|Acute Radiati... More >>on Syndrome Less << PHASE1 COMPLETED 2025-12-15 -
NCT00424177 - Completed - -
NCT01821625 Thrombocytopenia|Hepatitis C PHASE2|PHASE3 TERMINATED 2025-04-16 UT Southwestern Medical Center... More >>, Dallas, Texas, 75390-8887, United States Less <<
NCT00903929 Thrombocytopenia|Acute Radiati... More >>on Syndrome Less << PHASE1 COMPLETED 2025-12-15 -
NCT00888901 Idiopathic Thrombocytopenic Pu... More >>rpura Less << Phase 4 Completed - -
NCT00351468 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << Phase 3 Completed - -
NCT00351468 - Completed - -
NCT01439321 - Completed - -
NCT03206086 Fanconi Anemia PHASE2 ACTIVE_NOT_RECRUITING 2030-08-01 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT01484314 Thrombocytopenia|Multiple Myel... More >>oma Less << PHASE2 TERMINATED 2025-09-15 Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02215, United States Less <<
NCT01168921 CLL|Leukemia PHASE2 COMPLETED 2022-03-07 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01000051 Thrombocytopenia Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00996216 Hepatitis C Phase 3 Completed - -
NCT01484314 Thrombocytopenia|Multiple Myel... More >>oma Less << PHASE2 TERMINATED 2025-09-15 Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02215, United States Less <<
NCT01621204 Immune Thrombocytopenic Purpur... More >>a Less << Phase 3 Recruiting January 2019 Canada, Alberta ... More >> University of Alberta Hospital Recruiting Edmonton, Alberta, Canada, T6G2G3 Contact: Loree Larratt, MD    780-407-7021    llarratt@ualberta.ca    Contact: Ovais Shaikh    780-407-6090    Ovais.Shaikh@albertahealthservices.ca    Principal Investigator: Loree Laratt, MD          Sub-Investigator: Irwindeep Sandhu, MD          Canada, British Columbia Vancouver General Hospital Terminated Vancouver, British Columbia, Canada, V5Z1M9 Canada, Ontario Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L8N 3Z5 Contact: Donald M Arnold, MD    905-525-9140 ext 28603    arnold@mcmaster.ca    Contact: Erin Jamula, MSc    905-525-9140 ext 21845    jamulae@mcmaster.ca    Principal Investigator: Donald M Arnold, MD          London Health Sciences Center Recruiting London, Ontario, Canada, N6A5W9 Contact: Cyrus Hsia, MD    519-685-8500 ext 56060    cyrus.hsia@lhsc.on.ca    Contact: Maisam Abouzeenni       Maisam.Abouzeenni@lhsc.on.ca    Principal Investigator: Cyrus Hsia, MD          Ottawa Hospital Recruiting Ottawa, Ontario, Canada, K1H8L6 Contact: Alan Tinmouth, MD    613-737-8899 ext 73914    Atinmouth@toh.ca    Contact: Holly Carr       hcarr@ohri.ca    Principal Investigator: Alan Tinmouth, MD          Sunnybrook Hospital Recruiting Toronto, Ontario, Canada, M4N3M5 Contact: Yulia Lin, MD    416-480-6100 ext 2781    Yulia.Lin@sunnybrook.ca    Principal Investigator: Yulia Lin, MD          St.Micheal's Hospital Recruiting Toronto, Ontario, Canada, M5B1W8 Contact: Michelle Sholzberg, MD    416-864-6060    SholzbergM@smh.ca    Contact: Aziz Jiwajee    416-864-5354    JiwajeeA@smh.ca    Principal Investigator: Michelle Sholzberg, MD          Canada, Quebec Hopital Maisonneuve-Rosemont Recruiting Montreal, Quebec, Canada, H1T2M4 Contact: Jeannine Kassis, MD    514-252-3404    jkassis.hmr@ssss.gouv.qc.ca    Contact: Julie Trinh Lu, B.Sc, DESS    514-252-3400 ext 3336    jtlu.hmr@ssss.gouv.qc.ca    Principal Investigator: Jeannine Kassis, MD          Jewish General Hospital Recruiting Montreal, Quebec, Canada, H3T1E2 Contact: Mark Blostein, MD    514-340-8214    mark.blostein@mgill.ca    Contact: Vivian Pananis    514-340-8222 ext 5982    vpananis@gmail.com    Principal Investigator: Mark Blostein, MD          Netherlands The Haga Hospital Not yet recruiting The Hague, Netherlands Contact: Sufia Amini    31 702102556    s.amini@hagaziekenhuis.nl    Contact: Okke Eissen    31 702101844    o.eissen@hagaziekenhuis.nl    Principal Investigator: Martin Schipperus, MD Less <<
NCT00902018 Idiopathic Thrombocytopenic Pu... More >>rpura Less << Phase 2 Completed - United States, New York ... More >> Weill Cornell Medical College New York, New York, United States, 10065 Less <<
NCT00828750 - Completed - -
NCT01481220 Myelodysplastic Syndrome|Throm... More >>bocytopenia Less << PHASE1 COMPLETED 2025-05-13 4 Locations, Uppsala, Stockhol... More >>m, G?teborg, Ume?, Sweden Less <<
NCT02071901 Acute Myeloid Leukemia With Mu... More >>ltilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Basophilic Leukemia Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia Less << Phase 2 Active, not recruiting December 2018 United States, Ohio ... More >> Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 Less <<
NCT00922883 Anemia, Aplastic|Anemia, Hypop... More >>lastic|Thrombocytopenia Less << PHASE2 COMPLETED 2018-04-24 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00996216 - Completed - -
NCT00828750 Idiopathic Thrombocytopenic Pu... More >>rpura Purpura, Thrombocytopenic, Idiopathic Less << Phase 3 Completed - Japan ... More >> GSK Investigational Site Gifu, Japan, 503-8502 GSK Investigational Site Hiroshima, Japan, 734-8551 GSK Investigational Site Ibaraki, Japan, 305-8576 GSK Investigational Site Osaka, Japan, 565-0871 GSK Investigational Site Osaka, Japan, 596-8501 GSK Investigational Site Tokyo, Japan, 160-8582 Less <<
NCT00922883 Anemia, Aplastic|Anemia, Hypop... More >>lastic|Thrombocytopenia Less << PHASE2 COMPLETED 2018-04-24 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT01428635 Leukemia Chro... More >>nic Myeloid Leukemia Myelofibrosis Less << Phase 2 Active, not recruiting January 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00643929 Purpura, Thrombocytopaenic, Id... More >>iopathic Less << COMPLETED 2025-03-13 GSK Investigational Site, Tucs... More >>on, Arizona, 85724, United States|GSK Investigational Site, Washington, District of Columbia, 20007, United States|GSK Investigational Site, Detroit, Michigan, 48202, United States|GSK Investigational Site, Durham, North Carolina, 27710, United States|GSK Investigational Site, Richmond, Virginia, 23249, United States|GSK Investigational Site, Kogarah, New South Wales, 2217, Australia|GSK Investigational Site, Plovdiv, 4000, Bulgaria|GSK Investigational Site, Sofia, 1756, Bulgaria|GSK Investigational Site, Calgary, Alberta, T2N 4Z6, Canada|GSK Investigational Site, Victoria, British Columbia, V8V 3P9, Canada|GSK Investigational Site, Winnipeg, Manitoba, R3E 3P4, Canada|GSK Investigational Site, Halifax, Nova Scotia, B3H 2Y9, Canada|GSK Investigational Site, Montreal, Quebec, H2X 3J4, Canada|GSK Investigational Site, Brno, 656 53, Czech Republic|GSK Investigational Site, Praha 4, 140 21, Czech Republic|GSK Investigational Site, Praha 8, 180 81, Czech Republic|GSK Investigational Site, Caen, 14033, France|GSK Investigational Site, Clichy Cedex, 92118, France|GSK Investigational Site, Marseille Cedex 08, 13285, France|GSK Investigational Site, Paris Cedex 12, 75571, France|GSK Investigational Site, Pessac Cedex, 33604, France|GSK Investigational Site, Pessac, 33604, France|GSK Investigational Site, Rouen cedex, 76031, France|GSK Investigational Site, Vandoeuvre Les Nancy, 54511, France|GSK Investigational Site, Berlin, 13353, Germany|GSK Investigational Site, Shatin, New Territories, Hong Kong|GSK Investigational Site, Budapest, 1529, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Chennai, 600010, India|GSK Investigational Site, Kolkatta, 700 054, India|GSK Investigational Site, Mumbai, 400036, India|GSK Investigational Site, Avellino, Campania, 83100, Italy|GSK Investigational Site, Roma, Lazio, 00133, Italy|GSK Investigational Site, Genova, Liguria, 16132, Italy|GSK Investigational Site, Brescia, Lombardia, 25123, Italy|GSK Investigational Site, Milano, Lombardia, 20132, Italy|GSK Investigational Site, Milano, Lombardia, 20157, Italy|GSK Investigational Site, San Giovanni Rotondo, Puglia, 71013, Italy|GSK Investigational Site, Karachi, 75300, Pakistan|GSK Investigational Site, Lima, Lima 27, Peru|GSK Investigational Site, Lima, Lima 41, Peru|GSK Investigational Site, Poznan, 61-866, Poland|GSK Investigational Site, San Juan, 00909, Puerto Rico|GSK Investigational Site, Moscow, 105 229, Russian Federation|GSK Investigational Site, Moscow, 117997, Russian Federation|GSK Investigational Site, Moscow, 125167, Russian Federation|GSK Investigational Site, Saint-Petersburg, 191167, Russian Federation|GSK Investigational Site, Samara, 443011, Russian Federation|GSK Investigational Site, St'Petersburg, 191024, Russian Federation|GSK Investigational Site, St. Petersburg, 197758, Russian Federation|GSK Investigational Site, St. Petersburg, 198255, Russian Federation|GSK Investigational Site, Barcelona, 08907, Spain|GSK Investigational Site, Madrid, 28006, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, San Sebastián, 20014, Spain|GSK Investigational Site, Santa Cruz de Tenerife, 38320, Spain|GSK Investigational Site, Santiago de Compostela, 15706, Spain|GSK Investigational Site, Sevilla, 41014, Spain|GSK Investigational Site, Stockholm, SE-141 86, Sweden|GSK Investigational Site, Stockholm, SE-171 76, Sweden|GSK Investigational Site, Montfleury, 1008, Tunisia|GSK Investigational Site, Sfax, 3029, Tunisia|GSK Investigational Site, Sousse, 4000, Tunisia|GSK Investigational Site, Tunis, 1008, Tunisia|GSK Investigational Site, Dnipropetrovsk, 49102, Ukraine|GSK Investigational Site, Donetsk, 83114, Ukraine|GSK Investigational Site, Kyiv, 01030, Ukraine|GSK Investigational Site, Vinnytsia, 21021, Ukraine|GSK Investigational Site, Plymouth, Devon, PL6 8DH, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, G12 0YN, United Kingdom|GSK Investigational Site, London, NW1 2BU, United Kingdom|GSK Investigational Site, Morriston, SA6 6NL, United Kingdom Less <<
NCT01194167 Thrombocytopenia PHASE2 WITHDRAWN 2025-01-12 University of Cincinnati, Cinc... More >>innati, Ohio, 45219, United States Less <<
NCT01491594 Sarcoma, Soft Tissue|Osteosarc... More >>oma|Neoplasms, Connective and Soft Tissue Less << PHASE1 TERMINATED 2025-03-13 Duke Cancer Center, Durham, No... More >>rth Carolina, 27710, United States Less <<
NCT02998645 Severe Aplastic Anemia Phase 2 Recruiting January 12, 2024 Brazil ... More >> Novartis Investigative Site Recruiting Ribeirao Preto, SP, Brazil, 14048-900 Novartis Investigative Site Recruiting São Paulo, SP, Brazil, 01323-900 Hong Kong Novartis Investigative Site Recruiting Hong Kong, Hong Kong Hungary Novartis Investigative Site Recruiting Debrecen, Hungary, 4032 India Novartis Investigative Site Recruiting Vellore, India Italy Novartis Investigative Site Recruiting Bologna, BO, Italy, 40138 Novartis Investigative Site Recruiting Brescia, BR, Italy, 25123 Novartis Investigative Site Recruiting Milano, MI, Italy, 20122 Korea, Republic of Novartis Investigative Site Recruiting Seoul, Korea, Republic of, 06351 Netherlands Novartis Investigative Site Recruiting Leiden, Netherlands, 2300 RC Spain Novartis Investigative Site Recruiting San Sebastian, Pais Vasco, Spain, 20080 Novartis Investigative Site Recruiting Madrid, Spain, 28041 Novartis Investigative Site Recruiting Madrid, Spain, 28222 Thailand Novartis Investigative Site Recruiting Bangkok, Thailand, 10700 Novartis Investigative Site Recruiting Chiang Mai, Thailand, 50200 Turkey Novartis Investigative Site Recruiting Istanbul, Turkey, 34890 Novartis Investigative Site Recruiting Samsun, Turkey, 55139 Less <<
NCT01703169 Severe Aplastic Anemia|Very Se... More >>vere Aplastic Anemia|Moderate Aplastic Anemia Less << PHASE2 COMPLETED 2025-06-16 University of Utah, Salt Lake ... More >>City, Utah, 84112, United States Less <<
NCT01762761 Purpura, Thrombocytopenic, Idi... More >>opathic and Hepatitis C Less << Phase 3 Active, not recruiting November 15, 2018 China, Fujian ... More >> Novartis Investigative Site Fuzhou, Fujian, China, 350001 China, Guangdong Novartis Investigative Site Guangzhou, Guangdong, China, 510080 Novartis Investigative Site Guangzhou, Guangdong, China, 510515 Novartis Investigative Site Zhongshan, Guangdong, China, 528403 China, Hunan Novartis Investigative Site Changsha, Hunan, China, 410013 China, Jiangsu Novartis Investigative Site Nanjing, Jiangsu, China, 210029 China, Jiangxi Novartis Investigative Site Nanchang, Jiangxi, China, 330006 China, Shandong Novartis Investigative Site Jianan, Shandong, China, 250012 China, Zhejiang Novartis Investigative Site Hangzhou, Zhejiang, China, 310003 China Novartis Investigative Site Beijing, China, 100034 Novartis Investigative Site Beijing, China, 100044 Novartis Investigative Site Beijing, China, 100083 Novartis Investigative Site Beijing, China, 100730 Novartis Investigative Site Chengdu, China, 610041 Novartis Investigative Site Jiang Su Province, China, 215006 Novartis Investigative Site Shanghai, China, 200025 Novartis Investigative Site Shanghai, China Novartis Investigative Site Tianjin, China, 300020 Less <<
NCT02281370 Purpura, Thrombocytopenic, Idi... More >>opathic Less << Phase 1 Completed - United States, Kansas ... More >> GSK Investigational Site Overland Park, Kansas, United States, 66211 Less <<
NCT01055600 Thrombocytopaenia Phase 4 Withdrawn(Protocol opened to r... More >>ecruitment in Nov 2009. No potential subjects identified in 5 years; therefore, study was terminated in Jul 2014 due to lack of feasibility) Less << July 2014 United States, North Carolina ... More >> GSK Investigational Site Research Triangle Park, North Carolina, United States, 27709 Less <<
NCT01893372 Leukemia Phase 2 Active, not recruiting October 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01891994 Severe Aplastic Anemia (SAA) PHASE2 COMPLETED 2022-08-24 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT01550185 Adult Acute Basophilic Leukemi... More >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Recurrent Adult Acute Myeloid Leukemia Less << Phase 1 Terminated(Sponsor wanted stud... More >>y rewritten) Less << - United States, Georgia ... More >> Emory University, Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Less <<
NCT01286675 Multiple Myeloma EARLY_PHASE1 COMPLETED 2025-12-18 Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02215, United States Less <<
NCT01762761 - Active, not recruiting - -
NCT02404025 Cytopaenia Phase 2 Completed - Japan ... More >> Novartis Investigative Site Aichi, Japan, 453-8511 Novartis Investigative Site Aichi, Japan, 460-0001 Novartis Investigative Site Ibaraki, Japan, 305-8576 Novartis Investigative Site Ishikawa, Japan, 920-8641 Novartis Investigative Site Miyagi, Japan, 981-1293 Novartis Investigative Site Okayama, Japan, 700-0962 Novartis Investigative Site Osaka, Japan, 530-0012 Novartis Investigative Site Osaka, Japan, 543-8555 Novartis Investigative Site Osaka, Japan, 565-0871 Novartis Investigative Site Tochigi, Japan, 329-0498 Novartis Investigative Site Tokyo, Japan, 141-8625 Less <<
NCT03771378 Primary Immune Thrombocytopeni... More >>a Less << Phase 4 Not yet recruiting September 15, 2019 -
NCT01703169 Severe Aplastic Anemia|Very Se... More >>vere Aplastic Anemia|Moderate Aplastic Anemia Less << PHASE2 COMPLETED 2025-06-16 University of Utah, Salt Lake ... More >>City, Utah, 84112, United States Less <<
NCT03603795 Acute Myeloid Leukemia Phase 2 Recruiting September 2024 France ... More >> CHU ANGERS - Maladies du sang Not yet recruiting Angers, France, 49933 Contact: Mathilde HUNAULT, Dr    02 41 35 45 82    mahunault@chu-angers.fr    CH de la Côte Basque - Hématologie Not yet recruiting Bayonne, France, 64109 Contact: Anne BANOS, Dr    +33 5 59 44 38 32    abanos@ch-cotebasque.fr    CHU Estaing Not yet recruiting Clermont-Ferrand, France, 63003 Contact: Aurélie RAVINET, Dr    04 73 75 00 65    aravinet@chu-clermontferrand.fr    CHU Grenoble - Hématologie Clinique Recruiting Grenoble, France, 38043 Contact: Claude-Eric BULABOIS, Dr    04 76 76 57 55    cebulabois@chu-grenoble.fr    Institut Paoli-Calmettes - Hématologie 2 Not yet recruiting Marseille, France, 13000 Contact: Norbert VEY, Pr    +33 4 91 22 36 95    veyn@ipc.unicancer.fr    Hôpital Saint-Eloi - Hématologie Clinique Not yet recruiting Montpellier, France, 34295 Contact: Yosr HICHERI, Dr    +33 4 67 33 24 18    y-hicheri@chu-montpellier.fr    HOPITAL E. MULLER - Hématologie Not yet recruiting Mulhouse, France, 68070 Contact: Mario OJEDA-URIBE, Dr    +33(0)3 89 64 77 55    ojeda-uribem@ghrmsa.fr    CHU HOTEL DIEU - Hématologie Clinique Not yet recruiting Nantes, France, 44093 Contact: Pierre PETERLIN, Dr    +33(0)2 40 08 32 71    pierre.peterlin@chu-nantes.fr    CHU Caremeau Not yet recruiting Nîmes, France, 30029 Contact: Eric JOURDAN, Dr    04 66 68 32 31    eric.jourdan@chu-nimes.fr    CHU La Milétrie - Hématologie Clinique Not yet recruiting Poitiers, France, 86000 Contact: Maria-Pilar GALLEGO-HERNANZ, Dr    +33(0)5 49 44 44 44    maria-pilar.gallego-hernanz@chu-poitiers.fr    CHU Pontchaillou Not yet recruiting Rennes, France, 35033 Contact: Marc BERNARD, Dr    02 40 08 32 71    marc.bernard@chu-rennes.fr    CHU Hautepierre - Hématologie Not yet recruiting Strasbourg, France, 67098 Contact: Bruno LIOURE, Dr    +33(0)3 88 12 76 76    bruno.lioure@chru-strasbourg.fr    Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie Recruiting Toulouse, France, 31059 Contact: Christian RECHER, Pr    +33 5 31 15 63 55    recher.christian@iuct-oncopole.fr    Sponsor FILO Not yet recruiting Tours, France, 37044 Contact: Mélanie COTTOT, Mrs    +33247478899    m.dupin@chu-tours.fr    CHU de Brabois Not yet recruiting Vandœuvre-lès-Nancy, France, 54500 Contact: Caroline BONMATI, Dr    03 83 15 52 49    c.bonmati@chu-nancy.fr Less <<
NCT03754634 Thrombocytopenia Phase 2 Not yet recruiting September 1, 2020 China, Shandong ... More >> Qilu hospital, Shandong University Recruiting Jinan, Shandong, China Contact: Ming Hou, doctor       houming@medmail.com.cn Less <<
NCT01891994 Severe Aplastic Anemia (SAA) PHASE2 COMPLETED 2022-08-24 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT01386723 - Terminated - United States, New York ... More >> Weill Cornell Medical College/New York Presbyterian Hospital New York, New York, United States, 10065 Less <<
NCT01656252 - Terminated(Study stopped per N... More >>ovartis request due to futility from another study.) Less << - -
NCT01656252 Acute Myeloid Leukemia Phase 1 Phase 2 Terminated(Study stopped per N... More >>ovartis request due to futility from another study.) Less << - United States, Massachusetts ... More >> University of Massachusetts Worcester Worcester, Massachusetts, United States, 01655 United States, Minnesota Mayo Clinic, Rochester Rochester, Minnesota, United States, 55905 United States, Ohio University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 United States, Pennsylvania Penn State Hershey Cancer Institute Hershey, Pennsylvania, United States, 17033 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 Less <<
NCT01286038 Myelodysplastic Syndrome (MDS)... More >>|Thrombocytopenia Less << PHASE1 TERMINATED 2018-11-03 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT01652599 Immune Thrombocytopenic Purpur... More >>a Less << Phase 2 Completed - Mexico ... More >> Hospital Universitario "Dr. Jose E. Gonzalez" UANL Monterrey, Nuevo Leon, Mexico, 64460 Less <<
NCT02422394 Inherited Platelet Disorder PHASE2 COMPLETED 2025-03-18 Department of Internal Medicin... More >>e, Hospital of Padova, Padova, 35128, Italy|Unit of Internal Medicine 3, IRCCS Policlinico San Matteo Foundation, Pavia, 27100, Italy|Section of Internal and Cardiovascular Medicine, Department of Medicine, University Hospital of Perugia, Perugia, 06126, Italy Less <<
NCT02010645 Leukemia Phase 2 Active, not recruiting March 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02773225 Anemia, Aplastic Phase 2 Phase 3 Recruiting September 30, 2023 Germany ... More >> University Hospital Ulm Recruiting Ulm, Germany, 89081 Contact: Britta Höchsmann, MD       hoechsmann@blutspende.de Less <<
NCT01397149 Chronic Lymphocytic Leukemia ... More >> Thrombocytopenia Less << Phase 1 Phase 2 Terminated(Insufficient recrui... More >>tment) Less << - Austria ... More >> Medizinische Universität Wien, Innere Medizin I, Abt. Hämatologie und Hämastaseologie Vienna, Austria, 1090 Germany Universitätsklinikum Köln; Klinik I für Innere Medizin Cologne, Germany, 50924 Universitätsklinikum Carl Gustav Carus Med. Klinik und Poliklinik I Dresden, Germany, 01307 Gemeinschaftspraxis für Innere Medizin, Hämatologie und Internistische Onkologie Erlangen, Germany, 91052 Universitätsklinikum; Klinik für Hämatologie Essen, Germany, 45147 Klinikum Frankfurt (Oder) Medizinische Klinik I Frankfurt (Oder), Germany, 15236 Universitätsklinikum Schleswig-Holstein, II. Medizinische Klinik und Poliklinik im Städtischen Krankenhaus Kiel, Germany, 24116 Onkologische Schwerpunktpraxis Leer-Emden Leer, Germany, 26789 Städtisches Klinikum München GmbH, Klinikum Schwabing, Klinik für Hämatologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin München, Germany, 80804 Universitätsklinikum Ulm, Medizinische Klinik III Ulm, Germany, 89081 Less <<
NCT01133860 - Completed - -
NCT02201290 Purpura, Thrombocytopenic, Idi... More >>opathic Less << Phase 3 Completed - Russian Federation ... More >> Novartis Investigative Site Krasnodar, Russian Federation, 350007 Novartis Investigative Site Moscow, Russian Federation, 117997 Novartis Investigative Site Saint Petersburg, Russian Federation, 198205 Less <<
NCT03524612 Immune Thrombocytopenic Purpur... More >>a (ITP) Less << Phase 2 Recruiting November 16, 2020 United States, New York ... More >> Hematology Oncology Association of Rockland Drug Shipment Recruiting Nyack, New York, United States, 10960 Contact    845-348-2657       Principal Investigator: Bradley Cohen          Austria Novartis Investigative Site Recruiting A-1090 Vienna, Austria Novartis Investigative Site Recruiting Wien, Austria, 1140 Spain Novartis Investigative Site Recruiting Salamanca, Castilla Y Leon, Spain, 37007 Novartis Investigative Site Recruiting Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Recruiting Majadahonda, Madrid, Spain, 28222 Novartis Investigative Site Recruiting Malaga, Spain, 29010 Novartis Investigative Site Recruiting Murcia, Spain, 30008 Less <<
NCT02323178 CMML Thromboc... More >>ytopenia Less << Phase 1 Phase 2 Active, not recruiting December 2019 France ... More >> CHU d'Amiens Amiens, France, 80054 CHU d'Angers Angers, France, 49 033 CH Victor Dupouy Argenteuil, France, 95107 Hôpital Avicenne Bobigny, France, 93009 Hôpital privé Sévigné Cesson-Sévigné, France, 35510 CHU Henri Mondor Créteil, France, 94010 CHU de Grenoble Grenoble, France, 38043 CH Le Mans Le Mans, France, 72037 CHRU de Limoges Limoges, France, 87046 Centre Hospitalier Lyon Sud Lyon, France, 69495 Institut Paoli Calmettes Marseille, France, 13009 Centre Hospitalier de Meaux Meaux, France, 77100 CHU de Nantes Nantes, France, 44093 Centre Catherine de Sienne Nantes, France, 44277 Hôpital Archet 1 Nice, France, 06202 Hôpital Saint Louis - Service d'hématologie AJA Paris, France, 75010 Hôpital Saint Louis - Service d'hématologie séniors Paris, France, 75010 CHU de Haut-Lévèque Pessac, France, 33604 CHU de Poitiers Poitiers, France, 86021 Centre Hospitalier de la région d'Annecy Pringy cedex, France, 74374 Hôpital Pontchaillou Rennes, France, 35033 Centre Henri Becquerel Rouen, France, 76038 Hôpital Purpan - Médecine interne Toulouse, France, 31059 Hôpital Purpan - Service d'Hématologie Clinique Toulouse, France, 31059 CHU Brabois Vandoeuvre Les Nancy, France, 54511 Institut Gustave Roussy Villejuif, France, 94805 Less <<
NCT03412188 Idiopathic Thrombocytopenic Pu... More >>rpura Less << Not Applicable Recruiting November 2019 Egypt ... More >> Ainshams University , Faculty of medicine , Pediatric Hematology&Oncology unit, children hospital. Recruiting Cairo, Egypt, 11579 Contact: Micheal morcos, M.Sc       mekoo_828@yahoo.com    Contact: Mahmoud Kenny, MD       moudykenny@yahoo.com    Principal Investigator: Azza AG Tantawy, MD          Sub-Investigator: Nayera HK El Sherif, MD          Sub-Investigator: Fatma S Ebeid, MD          Sub-Investigator: Eman AR Ismail, MD          Sub-Investigator: Mahmoud A Kenny, MD          Sub-Investigator: Michael BE morcos, M.Sc Less <<
NCT01757145 Hematological Malignancy|Bone ... More >>Marrow Failure Syndrome Less << PHASE2 UNKNOWN 2025-06-16 Hadassah hospital, Jerusalem, ... More >>Israel|Davidof Cancer Center, Beilinson hospital, Rabin medical center, Petach Tikva, Israel Less <<
NCT01133860 Blood Platelet Disorders Phase 2 Completed - Italy ... More >> Azienda Ospedaliero-Universitaria di Padova, Unità di Medicina Generale e Patologia Speciale Padova, Italy, 35128 Fondazione IRCCS Policlinico San Matteo, Unità di Medicina III Pavia, Italy, 27100 Policlinico Monteluce, Sezione di Medicina Interna e Cardiovascolare Perugia, Italy, 06122 Less <<
NCT03515096 Eltrombopag H... More >>ematopoietic Stem Cell Transplantation Thrombocytopenia Less << Phase 3 Not yet recruiting June 1, 2021 -
NCT01940562 Pediatric Patients Undergoing ... More >>Allogeneic Cord Blood Transplantation. Less << Phase 2 Unknown June 2016 Israel ... More >> Hadassah hospital Recruiting Jerusalem, Israel Contact: Michael Shapira, MD    972-50-7874433       Schneider Children's Medical Center of Israel Recruiting Petah Tikva, Israel, 49202 Contact: Jerry Stein, MD    972-50-4057148    jstein@clalit.org.il    Principal Investigator: Jerry Stein, MD Less <<
NCT01791101 Thrombocytopenia PHASE2 COMPLETED 2020-06-26 UO Ematologia con trapianto-Un... More >>iversità degli Studi di Bari Aldo Moro, Bari, Italy|Divisione di Ematologia - Ospedali Riuniti, Bergamo, Italy|USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia, Brescia, Italy|Ospedale Santa Croce Divisione di Ematologia Cuneo, Catania, Italy|Ospedale Santa Croce Divisione di Ematologia Cuneo, Cuneo, Italy|Policlinico di Careggi, Firenze, Italy|Divisione Ematologia 2 - Azienda Ospedaliera Universitaria - S.Martino, Genova, Italy|Unità Trapianto di Midollo Ist. Nazionale Tumori, Milano, Italy|La Maddalena Casa di Cura di Alta Specialità Dipartimento Oncologico di III Livello, Palermo, Italy|U.O. Ematologia Clinica - Azienda USL di Pescara, Pescara, Italy|Università Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma, Italy|Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, Roma, Italy|Università degli Studi - Policlinico di Tor Vergata, Roma, Italy|Clinica Ematologica - Policlinico Universitario, Udine, Italy|ULSS N. 6 Ospedale S. Bortolo, Vicenza, Italy|ULSS N.6 Osp. S. Bortolo, Vicenza, Italy Less <<
NCT01488565 Myelodysplastic Syndromes (MDS... More >>) Acute Myeloid Leukaemia (AML) Less << Phase 2 Completed - Australia, Victoria ... More >> Peter MacCallum Cancer Centre East Melbourne, Victoria, Australia, 3002 Cabrini Hospital Malvern, Victoria, Australia, 3144 Less <<
NCT03413306 Acquired Aplastic Anemia Phase 3 Recruiting December 20, 2019 Russian Federation ... More >> Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology Recruiting Moscow, Russian Federation, 117198 Contact: Zhanna Shekhovtsova    4956647078    zhanna.shekhovtsova@fccho-moscow.ru    Contact: Eugene Pashanov, Prof. PhD    +79262205578    e.pashanov@gmail.com    Sub-Investigator: Olga Goronkova Less <<
NCT02148133 Cytopaenia Phase 2 Completed - Japan ... More >> Novartis Investigative Site Aichi, Japan, 453-8511 Novartis Investigative Site Aichi, Japan, 460-0001 Novartis Investigative Site Hyogo, Japan, 664-8540 Novartis Investigative Site Ibaraki, Japan, 305-8576 Novartis Investigative Site Ishikawa, Japan, 920-8641 Novartis Investigative Site Miyagi, Japan, 981-1293 Novartis Investigative Site Okayama, Japan, 700-0962 Novartis Investigative Site Osaka, Japan, 530-0012 Novartis Investigative Site Osaka, Japan, 543-8555 Novartis Investigative Site Osaka, Japan, 565-0871 Novartis Investigative Site Tochigi, Japan, 329-0498 Novartis Investigative Site Tokyo, Japan, 141-8625 Less <<
NCT03664518 Thrombocytopenia Purpura|Chron... More >>ic HBV Infection Less << PHASE2 COMPLETED 2022-09-30 Ethics Committee of Blood dise... More >>ase hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, 300020, China Less <<
NCT02254434 Cirrhosis, Liver PHASE1 COMPLETED 2014-09-08 GSK Investigational Site, Mexi... More >>co City, 14610, Mexico Less <<
NCT01880047 Immune Thrombocytopenia ... More >> Platelet Disorder Less << Phase 2 Active, not recruiting March 30, 2019 United States, New York ... More >> Weill Cornell Medicine New York, New York, United States, 10065 Less <<
NCT01500538 Follicular Lymphoma ... More >> Marginal Zone Lymphoma Mantle Cell Lymphoma Less << Phase 2 Terminated(Poor recruitment ra... More >>te) Less << - Australia, Victoria ... More >> Peter MacCallum Cancer Centre Melbourne, Victoria, Australia, 3002 Less <<
NCT03638817 Thrombocytopenia PHASE2 COMPLETED 2023-06-27 Angers Hospital, Angers, Franc... More >>e|Bensancon Hospital, Besan?on, France|Bordeaux Hospital, Bordeaux, France|Caen Hospital, Caen, France|Clermont-Ferrand Hospital, Clermont-Ferrand, France|Dijon Hospital, Dijon, France|Lille Hospital, Lille, France|Hospices Civils Lyon, Lyon, France|Marseille Hospital, Marseille, France|Montpellier Hospital, Montpellier, France|Nancy Hospital, Nancy, France|Nantes Hospital, Nantes, France|Cochin Hospital, Paris, France|Hopital Europeen G Pompidou, Paris, France|Kremlin Bicetre Hospital, Paris, France|Necker Hospital, Paris, France|Robert Debré Hospital, Paris, France|Trousseau Hospital, Paris, France|Poitiers Hospital, Poitiers, France|Reims Hospital, Reims, France|Rennes Hospital, Rennes, France|Rouen Hospital, Rouen, France|Strasbourg Hospital, Strasbourg, France|university hospital Toulouse, Toulouse, France|Tours Hospital, Tours, France Less <<
NCT01610180 Purpura, Thrombocytopenic, Idi... More >>opathic Autoimmune Thrombocytopenic Purpura Autoimmune Thrombocytopenia Chronic Lymphocytic Leukemia Non Hodgkin's Lymphoma Less << Phase 2 Completed - Italy ... More >> Department of Hematology, Ospedale San Bortolo Vicenza, Italy, 36100 Less <<
NCT03243656 Eltrombopag PHASE4 COMPLETED 2020-01-05 Facility of medicine, Assiut, ... More >>71511, Egypt Less <<
NCT03701217 Eltrombopag|Thrombocytopenia|A... More >>cute Myeloid Leukemia Less << PHASE2|PHASE3 UNKNOWN 2025-10-19 Department of Hematology,Nanfa... More >>ng Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China Less <<
NCT03437603 Poor Graft Function PHASE2 UNKNOWN 2025-01-20 the First Affiliated Hospital ... More >>of Soochow University, Suzhou, Jiangsu, China Less <<
NCT02402998 Primacy Immune Thrombocytopeni... More >>a Less << PHASE2 COMPLETED 2019-08-28 Azienda Ospedaliera Di Bologna... More >> Policlinico S. Orsola - Malpighi, Bologna, 40138, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano, Milano, Italy|Ospedale Niguarda " Ca Granda" - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano, Milano, Italy|Azienda Ospedaliera "S.Gerardo", Monza, Italy|Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Napoli, Italy|S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy|Azienda Ospedale S. Luigi at University of Torino, Orbassano, 10043, Italy|AO di Padova Università degli Studi Padova Dipartimento di Medicina Clinica Medica I - Medicina Interna CLOPD, Padova, Italy|Ospedale "Infermi", Rimini, Italy|Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, Roma, Italy|Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore, Rome, 00168, Italy|Clinica Ematologica-Centro Trapianti e Terapie cellulari Azienda Ospedaliero-Universitaria, Udine, Udine, Italy|Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi, Verona, Italy|Ospedale San Bortolo, Vicenza, 36100, Italy Less <<
NCT02093325 Solid Tumor Phase 3 Enrolling by invitation August 2019 Taiwan ... More >> Department of Obstetrics & Gynecology and Department of Oncology Chang Gung Memorial Hospital Chiayi City, Taiwan Department of Obstetrics & Gynecology Chang Gung Memorial Hospital Kaohsiung, Taiwan Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Division of Oncology Chang Gung Memorial Hospital Linkou, Taiwan Less <<
NCT03718533 Poor Graft Function PHASE2 TERMINATED 2020-11-03 Novartis Investigative Site, M... More >>alaga, Andalucia, 29010, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, 07120, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, Vigo, Pontevedra, 36212, Spain|Novartis Investigative Site, Barcelona, 08041, Spain Less <<
NCT01715779 Hepatitis C COMPLETED 2025-06-15 -
NCT03830749 Immune Thrombocytopenia PHASE2 COMPLETED 2023-03-31 Humanity & Health Research Cen... More >>tre, Hong Kong, Hong Kong SAR, Hong Kong Less <<
NCT00961064 Myelodysplastic Syndromes|Thro... More >>mbocytopenia Less << PHASE2 COMPLETED 2021-12-30 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT03988608 Aplastic Anemia PHASE2 COMPLETED 2023-05-17 Novartis Investigative Site, N... More >>anjing, Jiangsu, 210000, China|Novartis Investigative Site, Nanchang, Jiangxi, 330006, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Tianjin, 300020, China|Novartis Investigative Site, Tianjin, 300052, China Less <<
NCT04269889 Anemia, Diamond-Blackfan PHASE1|PHASE2 COMPLETED 2023-11-14 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT04837703 Thrombocytopenia AVAILABLE - -
NCT06493981 Aplastic Anemia Idiopathic PHASE3 NOT_YET_RECRUITING 2025-07-30 -
NCT06045052 Fanconi Anemia PHASE2 COMPLETED 2023-08-29 Hospital Infantil Universitari... More >>o Ni?o Jesús (HIUNJ), Madrid, 28009, Spain Less <<
NCT04600960 Chemotherapy-induced Thrombocy... More >>topenia|Eltrombopag Less << PHASE2 UNKNOWN 2023-12-31 Chinese Academy of Medical Sci... More >>ence and Blood Disease Hospital, Tianjin, Tianjin, 300020, China Less <<
NCT05286164 CART Treatment|B Cell Lymphoma PHASE2 UNKNOWN 2025-04-24 Tel-Aviv Sourasky Medicak cent... More >>er / BMT Unit, Tel-Aviv, 6423906, Israel Less <<
NCT04485416 Solid Tumor, Childhood|Solid T... More >>umor Less << PHASE1 RECRUITING 2025-12-24 University of California Davis... More >> Health System, Comprehensive Cancer Center, Sacramento, California, 95817, United States Less <<
NCT04102033 Immune Thrombocytopenia PHASE4 UNKNOWN 2021-01-01 -
NCT06458803 Refractory Thrombocytopenia|Co... More >>nnective Tissue Diseases Less << COMPLETED 2023-11-19 -
NCT03902041 Allogeneic Hematopoietic Stem ... More >>Cell Transplantation|Eltrombopag Less << UNKNOWN 2022-10-01 Heamtology Department, Provinc... More >>ial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.26mL

0.45mL

0.23mL

11.30mL

2.26mL

1.13mL

22.60mL

4.52mL

2.26mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories